OTLKOutlook Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Outlook Therapeutics, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OTLKThis | $112M#8 | — | — | 79.3x#10 | — | 17.2%#7 | -4744.3%#9 | — | -12.8%#2 | — | -64.7%#9 | — |
| STRO | $157M#1 | — | — | 1.5x#4 | 65.2%#2 | 15.9%#8 | -154.5%#4 | — | — | — | -12.9%#1 | — |
| TARA | $144M#2 | — | 0.9x#5 | 48.7x#8 | — | -28.7%#11 | -2189.6%#8 | -35.6%#5 | — | — | -52.4%#6 | — |
| CMPX | $138M#3 | — | 0.8x#4 | — | -100.0%#6 | -34.7%#12 | — | -40.0%#6 | — | — | -79.5%#13 | — |
| CHRS | $124M#4 | — | 2.0x#10 | 3.0x#6 | 59.8%#3 | 489.4%#1 | -429.5%#6 | 276.2%#3 | -351.2%#3 | — | -49.3%#5 | — |
| HUMA | $122M#5 | — | 3.9x#12 | 59.7x#9 | — | 72.5%#5 | -5306.0%#10 | -130.6%#12 | — | — | -72.4%#10 | — |
| ARMP | $114M#6 | — | — | — | — | -818.8%#16 | — | — | — | — | -35.9%#3 | 0.1%#1 |
| VYGR | $113M#7 | — | 0.7x#3 | 2.8x#5 | -49.5%#5 | -84.2%#14 | -326.6%#5 | -77.6%#10 | — | — | -59.9%#8 | — |
| AVXL | $112M#9 | — | 1.0x#7 | — | — | -7.8%#10 | — | -41.2%#7 | — | — | -84.4%#15 | — |
| LENZ | $110M#10 | — | 0.6x#2 | 5.8x#7 | — | -65.0%#13 | -477.5%#7 | -42.8%#8 | — | — | -87.5%#16 | — |
| ENGN | $109M#11 | 0.6x#1 | 0.5x#1 | — | — | -112.7%#15 | — | -50.9%#9 | — | — | -76.5%#12 | — |
| NMRA | $108M#12 | — | 2.4x#11 | — | — | -2.8%#9 | — | 532.2%#2 | -594.0%#4 | — | -80.8%#14 | — |
| BDTX | $104M#13 | — | 1.1x#8 | 1.5x#3 | — | 132.1%#3 | 17.9%#2 | 23276.9%#1 | — | — | -54.3%#7 | — |
| ATRA | $85M#14 | — | — | 0.7x#2 | -6.3%#4 | 138.3%#2 | 29.7%#1 | — | — | — | -38.9%#4 | — |
| TNYA | $82M#15 | — | 1.2x#9 | — | — | 18.5%#6 | — | -130.5%#11 | — | — | -74.2%#11 | — |
| VXRT | $80M#16 | 2.0x#2 | 1.0x#6 | 0.3x#1 | 726.7%#1 | 124.4%#4 | 7.6%#3 | 0.0%#4 | 22.5%#1 | — | -24.0%#2 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice